Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : PHAT save search
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Published: 2023-04-12 (Crawled : 14:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 3.16%
H: 5.42%
C: 3.06%
pharmaceuticals
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Published: 2023-04-04 (Crawled : 18:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 13.88%
H: 1.07%
C: -4.79%
update pharmaceuticals commercial
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
Published: 2023-01-03 (Crawled : 00:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 2.5%
H: 9.3%
C: 4.26%
pharmaceuticals drug application review update
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Published: 2022-09-26 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: -0.94%
H: 5.79%
C: 3.16%
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 0.0%
H: 3.03%
C: -3.5%
ALPN | $64.535 0.16% 0.16% 4M
|
Health Technology
|
| O: 0.15%
H: 2.17%
C: 0.14%
pharmaceuticals
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-08-02 (Crawled : 13:20) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: -7.94%
H: 0.48%
C: -22.63%
results
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Published: 2022-05-25 (Crawled : 13:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -4.39%
treatment fda
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 1.13%
H: 4.5%
C: 2.11%
phase 1 results phase 2 phase 3